Where is DIGMBIO located?

DIGMBIO is headquartered in Seongnam-si, South Korea.

Is DIGMBIO a funded company?

DIGMBIO is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does DIGMBIO rank among its competitors?

DIGMBIO ranks 2914th amongst 2641 active competitors, of which 907 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Erasca, which secured $45M in Mar, 2024.

Who are the top competitors of DIGMBIO?

DIGMBIO's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Juno Therapeutics. Among them, Erasca secured the most recent funding round in March, 2024.

DIGMBIO - 2026 Company Profile, Team & Competitors

DIGMBIO is a deadpooled company based in Seongnam-si (South Korea), founded in 2020. It operates as a Developer of therapeutics for multiple diseases. The company has 2641 active competitors, including 907 funded and 640 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Juno Therapeutics.

Company Details

Developer of therapeutics for multiple diseases. It offers pipeline of drug candidates which include DM3100 for Alzimer-s disease, DM1050 for NASH, and DM5167 for solid tumors. It offers molecular glue technology for targeted protein degradation drug to modulate protein-protein interactions.

Website: digmbio.com
Email ID: *****@digmbio.com
Phone Number: +82 **********

Key Metrics

Founded Year

2020

Location

Seongnam-si, South Korea

Stage

Deadpooled

Ranked

2914^th among 3250 competitors

Similar Companies

Madrigal Pharmaceuticals & 230 more

View DIGMBIO's full profile

DIGMBIO has not raised any funding rounds yet.

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of DIGMBIO include Jazz Pharmaceuticals, Sana Biotechnology and Juno Therapeutics. Here is the list of Top 10 competitors of DIGMBIO, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Prospect Venture Partners, Versant Ventures ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of genetically engineered cell therapies for multiple disorders	$821M	Bezos Expeditions, Google Ventures & 17 others	75/100
3rd	Juno Therapeutics 2013, Seattle (United States), Acquired	Global biopharmaceutical company discovering, developing, and delivering innovative medicines	$317M	RA Capital Management, BB Biotech & 14 others	74/100
4th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	74/100
5th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Third Rock Ventures, Nextech Invest & 20 others	72/100
6th	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$861M	Redmile Group, Fidelity Investments & 28 others	72/100
7th	MacroGenics 2000, Rockville (United States), Public	Developer of novel biologics for the treatment of autoimmune disorders, cancer and infectious disease	$126M	Nextech Venture, Ventures West & 29 others	71/100
8th	iTeos Therapeutics 2011, Cambridge (United States), Acquired	Developer of immunotherapy for treating cancer	$204M	RA Capital Management, Boxer Capital & 19 others	70/100
9th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Arch Venture Partners, Cormorant Asset Management ... & 13 others	70/100
10th	Replimune 2015, Oxford (United Kingdom), Public	Developer of oncolytic immunotherapies	$87M	Foresite Capital, Omega Funds & 7 others	70/100
2914th	DIGMBIO 2020, Seongnam-si (South Korea), Deadpooled	Developer of therapeutics for multiple diseases	-	-	16/100